...
机译:英夫利昔单抗BioSimilar CT-P13的可比免疫功能抑制:对炎症性肠病治疗的影响
Celltrion Inc R&
D Div 13-1 Songdo Dong Incheon 406840 South Korea;
Celltrion Inc R&
D Div 13-1 Songdo Dong Incheon 406840 South Korea;
Celltrion Inc R&
D Div 13-1 Songdo Dong Incheon 406840 South Korea;
Celltrion Inc R&
D Div 13-1 Songdo Dong Incheon 406840 South Korea;
Celltrion Inc R&
D Div 13-1 Songdo Dong Incheon 406840 South Korea;
Celltrion Inc R&
D Div 13-1 Songdo Dong Incheon 406840 South Korea;
Celltrion Inc R&
D Div 13-1 Songdo Dong Incheon 406840 South Korea;
Celltrion Inc R&
D Div 13-1 Songdo Dong Incheon 406840 South Korea;
Celltrion Inc R&
D Div 13-1 Songdo Dong Incheon 406840 South Korea;
Celltrion Inc R&
D Div 13-1 Songdo Dong Incheon 406840 South Korea;
Celltrion Inc R&
D Div 13-1 Songdo Dong Incheon 406840 South Korea;
Celltrion Inc R&
D Div 13-1 Songdo Dong Incheon 406840 South Korea;
Celltrion Inc R&
D Div 13-1 Songdo Dong Incheon 406840 South Korea;
Inha Univ Sch Med Translat Res Ctr Incheon South Korea;
Korea Adv Inst Sci &
Technol Grad Sch Med Sci &
Engn Lab Immunol &
Infect Dis Daejeon South;
Daehang Hosp Dept Gastroenterol Seoul South Korea;
Tel Aviv Univ Sheba Med Ctr Dept Gastroenterol Ramat Gan Israel;
Tel Aviv Univ Sheba Med Ctr Dept Gastroenterol Ramat Gan Israel;
Tel Aviv Univ Sheba Med Ctr Dept Gastroenterol Ramat Gan Israel;
Tel Aviv Univ Sheba Med Ctr Dept Gastroenterol Ramat Gan Israel;
Celltrion Inc R&
D Div 13-1 Songdo Dong Incheon 406840 South Korea;
CT-P13; infliximab; biosimilar; inflammatory bowel disease; biosimilarity; ADCC;
机译:英夫利昔单抗BioSimilar CT-P13的可比免疫功能抑制:对炎症性肠病治疗的影响
机译:CT-P13:治疗炎症性肠病的生物仿制性与英夫利昔单抗的综述
机译:生物纤维单纤维生素,CT-P13,治疗炎性肠病
机译:用于炎症性肠病infliximab的适应症
机译:血清和粪便生物标志物预测对炎症肠病小儿患者的英夫利昔单抗疗法的反应
机译:英夫利昔单抗生物仿制药CT-P13在治疗炎症性肠病方面是有效和安全的:在意大利原发性炎症性肠病中心进行的现实多中心观察性研究
机译:用参考生物制剂或生物蛋白质CT-P13治疗的患者的p633抗体对炎症性肠病的生物综合体CT-P13和SB2具有相同的反应性